Go to the list of all blogs
Rick Johnson's Avatar
published in Blogs
Sep 25, 2026
TickeronGET DAILY SIGNALS
AtriCure (ATRC) +26% Surge Over 30 Days: Key Drivers and Outlook

AtriCure (ATRC) +26% Surge Over 30 Days: Key Drivers and Outlook

Key Takeaways

  • AtriCure (ATRC) shares climbed roughly 26% over the last 30 days, rising from about $48.17 to a closing level near $60.77.
  • The rally has been part of a broader multi-month advance, with the stock trading at or near 52-week highs through mid-to-late September 2026.
  • Strong second-quarter results, a raised 2026 revenue outlook, and the addition of ATRC to the S&P 1000 index have supported the move.
  • New-product momentum in pain management and appendage management, along with a new surgical quality metric, are underpinning investor optimism.
  • Even after the surge, most covering analysts maintain a Buy rating, though consensus price targets sit below the current trading price, highlighting valuation debate.

Company Background and Market Focus

AtriCure, Inc. is a Mason, Ohio-based medical device company focused on the surgical treatment of atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management. Founded in 1994, the company sells radiofrequency and cryoablation systems used by cardiac and thoracic surgeons during open-heart and minimally invasive procedures.

Its flagship Isolator Synergy Ablation System was the first medical device to receive FDA approval for the treatment of persistent Afib, while its AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices globally. The company also markets the cryoICE, cryoSPHERE, and cryoXT cryo nerve block probes for pain relief, as well as the EnCompass clamp and EPi-Sense systems. Afib affects more than 59 million people worldwide, giving ATRC a large addressable market and a differentiated position in cardiac surgery. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Recent Stock Price Moves: 30 Days and the Quarter

Over the last 30 days, ATRC advanced roughly 26%, moving from a closing price of about $48.17 to approximately $60.77. The climb was broad and consistent, punctuated by a notable surge in trading volume in mid-September as the shares pushed into new 52-week high territory.

The strength extends well beyond the past month. Over the last quarter, the stock has more than doubled, rising from the high-$20s in late June to around $61. This momentum reflects sustained execution and a series of catalysts rather than a single isolated event, though the steep ascent has also raised valuation questions among some analysts. From what I see, this kind of sustained move often signals deeper operational progress worth monitoring.

Key Catalysts Behind the Last 30 Days

Several verified developments fueled the recent advance. AtriCure delivered strong second-quarter results, reporting revenue of approximately $153.6 million, up 12.8% year over year, and raised its full-year 2026 revenue guidance to a range of $600 million to $610 million, up from $534 million in 2025.

The Society of Thoracic Surgeons (STS) added concomitant Afib treatment as a quality metric in cardiac surgery, a change management believes will support increased adoption of surgical ablation and appendage management. In late September, AtriCure was added to the S&P 1000 index, a move typically associated with buying from index-tracking funds and a likely contributor to the elevated volume seen around that period.

Analyst commentary has remained supportive, with firms such as Needham and Canaccord Genuity maintaining Buy ratings. The competitive threat from Edwards Lifesciences (EW), which received FDA 510(k) clearance for its ECLIPTIS LAA exclusion system, was viewed by analysts as having minimal near-term impact on AtriCure's dominant AtriClip franchise. Earlier competitive entries from Medtronic (MDT) similarly failed to gain meaningful traction.

Drivers of the Broader Quarterly Advance

The multi-month rally has been driven by a larger narrative of accelerating growth and expanding profitability. AtriCure's pain management franchise has consistently outperformed expectations, led by the cryoSPHERE MAX probe, while the AtriClip FLEX-Mini and PRO-Mini devices have driven share gains in appendage management. The company has also stated it is running ahead of its long-range plan on both revenue and profitability.

Progress on pivotal clinical trials, including the LeAAPS and BoxX-NoAF studies, has reinforced confidence in a meaningfully larger total addressable market. Management has indicated these data catalysts may arrive sooner than originally expected, supporting the stock's re-rating over the quarter. I’m watching this closely as trial timelines can shift sentiment quickly.

Forward-Looking Factors for Investors

Looking ahead, investors will likely monitor several key factors. Upcoming quarterly earnings and any updates to the 2026 revenue and adjusted EBITDA guidance will be closely watched, given the stock's elevated valuation. Clinical data from the LeAAPS and BoxX-NoAF trials represent potential long-term catalysts, as positive readouts could expand the addressable market and support reimbursement.

Competitive dynamics in LAA management, including the phased commercial launch of Edwards' device, and the ongoing headwinds from pulsed field ablation in the minimally invasive ablation business, are also worth tracking. The STS quality metric's evolution toward a star-rating system could provide a durable tailwind. Finally, valuation remains a central debate, as the shares trade at a premium to consensus price targets despite strong operational momentum.

Exploring AI Tools for Market Analysis

In my view, incorporating data-driven resources can help clarify patterns amid volatility. I have found Tickeron’s AI tools useful for scanning opportunities and reviewing signals across sectors. One area worth a closer look is their selection of automated strategies, which covers a range of approaches and timeframes. This can serve as a practical starting point when evaluating how different models align with individual styles, whether focused on shorter-term moves or longer holds.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ATRC

ATRC's RSI Oscillator recovers from overbought zone

The 10-day RSI Indicator for ATRC moved out of overbought territory on November 05, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 instances where the indicator moved out of the overbought zone. In 27 of the 30 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ATRC as a result. In 69 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.

The Moving Average Convergence Divergence Histogram (MACD) for ATRC turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 34 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 76%.

ATRC moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ATRC crossed bearishly below the 50-day moving average on November 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATRC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

ATRC broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +9.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where ATRC advanced for three days, in 212 of 301 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.

The Aroon Indicator entered an Uptrend today. In 183 of 244 cases where ATRC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. ATRC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.766) is normal, around the industry mean (4.964). ATRC's P/E Ratio (266.091) is considerably higher than the industry average of (40.591). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.006) among similar stocks. P/S Ratio (4.869) is also within normal values, averaging (56.876).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATRC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 9.78B. The market cap for tickers in the group ranges from 126 to 159.96B. ISRG holds the highest valuation in this group at 159.96B. The lowest valued company is HGYMF at 126.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -8%. For the same Industry, the average monthly price growth was -5%, and the average quarterly price growth was 4%. STXS experienced the highest price growth at 12%, while RGNT experienced the biggest fall at -42%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 21%. For the same stocks of the Industry, the average monthly volume growth was 3% and the average quarterly volume growth was -39%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 53
Price Growth Rating: 52
SMR Rating: 81
Profit Risk Rating: 94
Seasonality Score: 18 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of surgical and medical instruments

Industry PharmaceuticalsOther

Industry
Medical Specialties
Address
7555 Innovation Way
Phone
+1 513 755-4100
Employees
1350
Web
https://www.atricure.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.